Home World News EMA Recommends Granting a Marketing Authorisation for Aumolertinib World News EMA Recommends Granting a Marketing Authorisation for Aumolertinib By Ogkologos - January 8, 2026 582 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Ibrutinib-Containing Immunochemotherapy in Front-Line Treatment of Young, Medically Fit Patients with... May 14, 2024 Foodie Friday: Winter Warm-Up White Bean Soup February 11, 2022 New treatment for Waldenstrom’s macroglobulinaemia in England October 1, 2022 Tables Turned June 23, 2020 Load more HOT NEWS Why haven’t we cured cancer? LGBTQ+ Voices: Listening to Sexual and Gender Minority People Affected by... Inpatient Mammography May Help Solve Issue of Low Screening Rates, Especially... How to Strengthen Your Immune System: Part 2
